Boston Medical Center
- Type
- Teaching hospital
- Where
- Boston, MA
- Medicare CCN
- 220031
- Received
- $7,049,386 in 501 records, 2022 ($1,002,282 general, $6,047,104 research)
- Source
- CMS Open Payments search ↗
On this site
- Business registration: Boston Medical Center Corporation Fuzzy (name and state)
- Business registration: BOSTON MEDICAL CENTER CORPORATION Fuzzy (name and state)
- Business registration: BOSTON MEDICAL CENTER CORPORATION Fuzzy (name and state)
- Business registration: BOSTON MEDICAL CENTER CORPORATION Fuzzy (name and state)
- Business registration: BOSTON MEDICAL CENTER CORPORATION Fuzzy (name and state)
- Nonprofit contractor: BOSTON MEDICAL CENTER Fuzzy (name and state)
- Plan sponsor: BOSTON MEDICAL CENTER Fuzzy (name and state)
- Federal award recipient: BOSTON MEDICAL CENTER Fuzzy (name and state)
- Federal award recipient: BOSTON MEDICAL CENTER CORPORATION Fuzzy (name and state)
- Lobbying client: BOSTON MEDICAL CENTER Fuzzy (name and state)
- Lobbying client: BOSTON MEDICAL CENTER Fuzzy (name and state)
- Lobbying client: BOSTON MEDICAL CENTER Fuzzy (name and state)
- Lobbying client: BOSTON MEDICAL CENTER Fuzzy (name and state)
- Lobbying client: BOSTON MEDICAL CENTER Fuzzy (name and state)
- Lobbying client: BOSTON MEDICAL CENTER Fuzzy (name and state)
- Lobbying client: BOSTON MEDICAL CENTER Fuzzy (name and state)
- Nonprofit: BOSTON MEDICAL CENTER CORPORATION Fuzzy (name and state)
- Patent assignee: BOSTON MEDICAL CENTER CORPORATION Fuzzy (name and state)
- Trademark owner: Boston Medical Center Corporation Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2022 | General payment | 75 | $1,002,282 |
| 2022 | Research payment | 426 | $6,047,104 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 426 | $6,047,104 |
| Grant | 8 | $881,889 |
| Education | 37 | $56,642 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 11 | $54,963 |
| Space rental or facility fees (teaching hospital only) | 1 | $4,500 |
| Travel and Lodging | 2 | $2,114 |
| Charitable Contribution | 10 | $1,281 |
| Food and Beverage | 4 | $686 |
| Debt forgiveness | 2 | $205 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2022-12-31 | Gilead Sciences, Inc. | $513,139 | Grant | Cash or cash equivalent | 2022 | ||
| 2022-12-31 | Merck Sharp & Dohme LLC | $78,889 | Research payment | In-kind items and services | GARDASIL 9 Biological, VACCINE | An Open-Label Clinical Trial Evaluating the Immunogenicity of the 9-valent 2-dose Vaccination Regimen over 6 months Amon | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $71,426 | Research payment | In-kind items and services | Characterization of Systemic and Local Immune Responses to Chlamydia Antigens in Women to support Vaccine Antigen Select | 2022 | |
| 2022-12-31 | Merck Sharp & Dohme LLC | $25,285 | Research payment | In-kind items and services | GARDASIL 9 Biological, VACCINE | An Exploratory Open-Label Clinical Trial Evaluating the Immunogenicity of the 9vHPV Vaccination 2-dose Regimen over a Fo | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $21,354 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab MK-3475 versus Placebo as A | 2022 |
| 2022-12-31 | KARL STORZ Endoscopy-America | $13,059 | Education | In-kind items and services | 2022 | ||
| 2022-12-31 | Merck Sharp & Dohme LLC | $11,642 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-79 | 2022 |
| 2022-12-31 | RedDress LTD | $8,131 | Research payment | Cash or cash equivalent | A Multi-Center, Prospective, Randomized, Controlled, Trial, Comparing the Safety and Efficacy of ActiGraft Pro to Standa | 2022 | |
| 2022-12-31 | Merck Sharp & Dohme LLC | $7,454 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab MK-3475 versus Placebo as A | 2022 |
| 2022-12-31 | KARL STORZ Endoscopy-America | $6,408 | Education | In-kind items and services | 2022 | ||
| 2022-12-31 | Merck Sharp & Dohme LLC | $6,323 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab MK-3475 versus Placebo as A | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $4,360 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-79 | 2022 |
| 2022-12-31 | KARL STORZ Endoscopy-America | $3,638 | Education | In-kind items and services | 2022 | ||
| 2022-12-31 | KARL STORZ Endoscopy-America | $3,016 | Education | In-kind items and services | 2022 | ||
| 2022-12-31 | Philips North America LLC | $3,000 | Research payment | In-kind items and services | (6260) Ingenia 3 0T R5 Device, Medical Device | WF-010536 / Evaluation of Image Quality of 3D Synthetic MRI in Children | 2022 |
| 2022-12-31 | KARL STORZ Endoscopy-America | $2,994 | Education | In-kind items and services | 2022 | ||
| 2022-12-31 | KARL STORZ Endoscopy-America | $2,876 | Education | In-kind items and services | 2022 | ||
| 2022-12-31 | KARL STORZ Endoscopy-America | $2,773 | Education | In-kind items and services | 2022 | ||
| 2022-12-31 | KARL STORZ Endoscopy-America | $2,183 | Education | In-kind items and services | 2022 | ||
| 2022-12-31 | KARL STORZ Endoscopy-America | $2,073 | Education | In-kind items and services | 2022 | ||
| 2022-12-31 | KARL STORZ Endoscopy-America | $2,029 | Education | In-kind items and services | 2022 | ||
| 2022-12-31 | KARL STORZ Endoscopy-America | $2,022 | Education | In-kind items and services | 2022 | ||
| 2022-12-31 | KARL STORZ Endoscopy-America | $1,852 | Education | In-kind items and services | 2022 | ||
| 2022-12-31 | KARL STORZ Endoscopy-America | $1,660 | Education | In-kind items and services | 2022 | ||
| 2022-12-31 | KARL STORZ Endoscopy-America | $1,660 | Education | In-kind items and services | 2022 | ||
| 2022-12-31 | KARL STORZ Endoscopy-America | $1,547 | Education | In-kind items and services | 2022 | ||
| 2022-12-31 | KARL STORZ Endoscopy-America | $1,411 | Education | In-kind items and services | 2022 | ||
| 2022-12-31 | Philips North America LLC | $1,200 | Research payment | In-kind items and services | (6260) Ingenia 3 0T R5 Device, Medical Device | WF-010536 / Evaluation of Image Quality of 3D Synthetic MRI in Children | 2022 |
| 2022-12-31 | ABBVIE INC. | $1,000 | Research payment | In-kind items and services | Safety And Efficacy Study Of Intravenous (IV) Administration Of Elezanumab To Assess Change In Upper Extremity Motor Sco | 2022 | |
| 2022-12-31 | KARL STORZ Endoscopy-America | $872 | Education | In-kind items and services | 2022 | ||
| 2022-12-31 | KARL STORZ Endoscopy-America | $872 | Education | In-kind items and services | 2022 | ||
| 2022-12-31 | KARL STORZ Endoscopy-America | $814 | Education | In-kind items and services | 2022 | ||
| 2022-12-31 | KARL STORZ Endoscopy-America | $490 | Education | In-kind items and services | 2022 | ||
| 2022-12-31 | KARL STORZ Endoscopy-America | $361 | Education | In-kind items and services | 2022 | ||
| 2022-12-31 | KARL STORZ Endoscopy-America | $314 | Education | In-kind items and services | 2022 | ||
| 2022-12-31 | KARL STORZ Endoscopy-America | $314 | Education | In-kind items and services | 2022 | ||
| 2022-12-31 | KARL STORZ Endoscopy-America | $281 | Education | In-kind items and services | 2022 | ||
| 2022-12-31 | KARL STORZ Endoscopy-America | $189 | Education | In-kind items and services | 2022 | ||
| 2022-12-31 | Merck Sharp & Dohme LLC | $149 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2022 |
| 2022-12-31 | KARL STORZ Endoscopy-America | $125 | Education | In-kind items and services | 2022 | ||
| 2022-12-31 | KARL STORZ Endoscopy-America | $124 | Education | In-kind items and services | 2022 | ||
| 2022-12-31 | KARL STORZ Endoscopy-America | $101 | Education | In-kind items and services | 2022 | ||
| 2022-12-31 | KARL STORZ Endoscopy-America | $101 | Education | In-kind items and services | 2022 | ||
| 2022-12-31 | KARL STORZ Endoscopy-America | $101 | Education | In-kind items and services | 2022 | ||
| 2022-12-31 | KARL STORZ Endoscopy-America | $101 | Education | In-kind items and services | 2022 | ||
| 2022-12-31 | KARL STORZ Endoscopy-America | $65 | Education | In-kind items and services | 2022 | ||
| 2022-12-31 | KARL STORZ Endoscopy-America | $57 | Education | In-kind items and services | 2022 | ||
| 2022-12-31 | KARL STORZ Endoscopy-America | $57 | Education | In-kind items and services | 2022 | ||
| 2022-12-31 | KARL STORZ Endoscopy-America | $40 | Education | In-kind items and services | 2022 | ||
| 2022-12-31 | KARL STORZ Endoscopy-America | $24 | Education | In-kind items and services | 2022 | ||
| 2022-12-31 | KARL STORZ Endoscopy-America | $21 | Education | In-kind items and services | 2022 | ||
| 2022-12-30 | C. R. Bard, Inc. & Subsidiaries | $1,911 | Research payment | Cash or cash equivalent | Arctic Sun 5000 Device, Medical Systems | INTREPID BMD1111 | 2022 |
| 2022-12-30 | PFIZER INC. | $1,434 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIA | 2022 | |
| 2022-12-28 | Novo Nordisk AS | $23 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4352 | 2022 |
| 2022-12-28 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4352 | 2022 |
| 2022-12-27 | G1 Therapeutics, Inc. | $12,403 | Research payment | Cash or cash equivalent | COSELA Drug, ONCOLOGY | A Phase 3, Randomized, Double-Blind Study of COSELA or Placebo in Patients Receiving First- or Second-Line Gemcitabine a | 2022 |
| 2022-12-22 | Boston Scientific Corporation | $100 | Charitable Contribution | Cash or cash equivalent | 2022 | ||
| 2022-12-21 | PFIZER INC. | $6,280 | Research payment | Cash or cash equivalent | PAXLOVID Drug, INFECTIOUS DISEASES | A PHASE 23 INTERVENTIONAL SAFETY PHARMACOKINETICS AND EFFICACY OPENLABEL MULTICENTER SINGLEARM STUDY TO INVESTIGATE ORAL | 2022 |
| 2022-12-21 | Novo Nordisk AS | $1,925 | Research payment | Cash or cash equivalent | Ozempic Drug, Diabetes | NN9535-4352 | 2022 |
| 2022-12-21 | TerSera Therapeutics LLC | $1,404 | Research payment | Cash or cash equivalent | Xermelo Drug, Oncology | A Phase 2, Multicenter, open-label, safety and efficacy study of Xermelo (telotristat ethyl) plus first-line chemotherap | 2022 |
| 2022-12-20 | Janssen Research & Development, LLC | $952 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide Bortezo | 2022 |
| 2022-12-20 | Boston Scientific Corporation | $100 | Charitable Contribution | Cash or cash equivalent | 2022 | ||
| 2022-12-19 | PFIZER INC. | $226,180 | Research payment | Cash or cash equivalent | SURVEILLANCE OF PNEUMOCOCCAL COLONIZATION IN CHILDREN LESS THAN 5 YEARS OF AGE AT BOSTON MEDICAL CENTER | 2022 | |
| 2022-12-19 | Merck Sharp & Dohme LLC | $5,149 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab MK-3475 versus Placebo as A | 2022 |
| 2022-12-16 | PFIZER INC. | $2,300 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY IN | 2022 |
| 2022-12-16 | Organon Llc | $1,460 | Research payment | Cash or cash equivalent | 8415-060 | 2022 | |
| 2022-12-16 | PFIZER INC. | $1,020 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT | 2022 |
| 2022-12-14 | PFIZER INC. | $10,716 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VAC | 2022 |
| 2022-12-14 | PFIZER INC. | $4,734 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB | 2022 |
| 2022-12-12 | Boston Scientific Corporation | $100 | Charitable Contribution | Cash or cash equivalent | 2022 | ||
| 2022-12-10 | PFIZER INC. | $21,836 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED | 2022 | |
| 2022-12-09 | PFIZER INC. | $6,077 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT | 2022 |
| 2022-12-08 | Takeda Pharmaceuticals U.S.A., Inc. | $516 | Research payment | Cash or cash equivalent | A PHASE-III, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, INTERNATIONAL, MULTICENTRE STUDY TO ASSESS EF | 2022 | |
| 2022-12-08 | Novo Nordisk AS | $23 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4352 | 2022 |
| 2022-12-08 | Novo Nordisk AS | $2 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4352 | 2022 |
| 2022-12-07 | PFIZER INC. | $11,880 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB | 2022 |
| 2022-12-07 | Merge Healthcare Incorporated | $15 | Food and Beverage | Cash or cash equivalent | Software Device, Medical Imaging | 2022 | |
| 2022-12-06 | PFIZER INC. | $6,000 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIA | 2022 | |
| 2022-12-02 | Boston Scientific Corporation | $100 | Charitable Contribution | Cash or cash equivalent | 2022 | ||
| 2022-12-01 | Regeneron Pharmaceuticals, Inc. | $54,720 | Research payment | Cash or cash equivalent | A MASTER PROTOCOL ASSESSING THE SAFETY, TOLERABILITY, AND EFFICACY OF ANTI-SPIKE (S) SARS-COV-2 MONOCLONAL ANTIBODIES FO | 2022 | |
| 2022-12-01 | Indivior Inc. | $5,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | SUBLOCADE Drug, OUD | 2022 | |
| 2022-12-01 | Indivior Inc. | $4,963 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | SUBLOCADE Drug, OUD | 2022 | |
| 2022-12-01 | PFIZER INC. | $487 | Research payment | Cash or cash equivalent | PAXLOVID Drug, INFECTIOUS DISEASES | A PHASE 23 INTERVENTIONAL SAFETY PHARMACOKINETICS AND EFFICACY OPENLABEL MULTICENTER SINGLEARM STUDY TO INVESTIGATE ORAL | 2022 |
| 2022-12-01 | Novo Nordisk AS | $23 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4352 | 2022 |
| 2022-12-01 | Novo Nordisk AS | $2 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4352 | 2022 |
| 2022-11-30 | Merck Sharp & Dohme LLC | $26,273 | Research payment | Cash or cash equivalent | LENVIMA Drug, ONCOLOGY | A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-79 | 2022 |
| 2022-11-30 | PFIZER INC. | $12,239 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VAC | 2022 |
| 2022-11-30 | Novo Nordisk AS | $3,075 | Research payment | Cash or cash equivalent | Ozempic Drug, Diabetes | NN9535-4352 | 2022 |
| 2022-11-29 | Boston Scientific Corporation | $154 | Charitable Contribution | Cash or cash equivalent | 2022 | ||
| 2022-11-23 | G1 Therapeutics, Inc. | $16,471 | Research payment | Cash or cash equivalent | COSELA Drug, ONCOLOGY | A Phase 3, Randomized, Double-Blind Study of COSELA or Placebo in Patients Receiving First- or Second-Line Gemcitabine a | 2022 |
| 2022-11-23 | PFIZER INC. | $7,976 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VAC | 2022 |
| 2022-11-23 | Intercept Pharmaceuticals, Inc. | $1,867 | Research payment | Cash or cash equivalent | OCALIVA Drug, Hepatology / Gastroenterology | Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) | 2022 |
| 2022-11-22 | PFIZER INC. | $18,230 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VAC | 2022 |
| 2022-11-22 | Novo Nordisk AS | $180 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4352 | 2022 |
| 2022-11-22 | Novo Nordisk AS | $180 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4352 | 2022 |
| 2022-11-22 | Novo Nordisk AS | $180 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4352 | 2022 |
| 2022-11-22 | Novo Nordisk AS | $180 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4352 | 2022 |
| 2022-11-22 | Novo Nordisk AS | $180 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4352 | 2022 |
| 2022-11-22 | Novo Nordisk AS | $180 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4352 | 2022 |
| 2022-11-22 | Novo Nordisk AS | $180 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4352 | 2022 |
| 2022-11-22 | Novo Nordisk AS | $180 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4352 | 2022 |
| 2022-11-22 | Novo Nordisk AS | $180 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4352 | 2022 |
| 2022-11-22 | Novo Nordisk AS | $180 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4352 | 2022 |
| 2022-11-22 | Novo Nordisk AS | $180 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4352 | 2022 |
| 2022-11-22 | Novo Nordisk AS | $180 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4352 | 2022 |
| 2022-11-22 | Novo Nordisk AS | $180 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4352 | 2022 |
| 2022-11-22 | Novo Nordisk AS | $180 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4352 | 2022 |
| 2022-11-22 | Novo Nordisk AS | $180 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4352 | 2022 |
| 2022-11-22 | Novo Nordisk AS | $180 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4352 | 2022 |
| 2022-11-22 | Novo Nordisk AS | $180 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4352 | 2022 |
| 2022-11-22 | Novo Nordisk AS | $180 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4352 | 2022 |
| 2022-11-22 | Novo Nordisk AS | $180 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4352 | 2022 |
| 2022-11-22 | Novo Nordisk AS | $180 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4352 | 2022 |
| 2022-11-22 | Novo Nordisk AS | $180 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4352 | 2022 |
| 2022-11-22 | Novo Nordisk AS | $180 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4352 | 2022 |
| 2022-11-22 | Novo Nordisk AS | $180 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4352 | 2022 |
| 2022-11-22 | Novo Nordisk AS | $180 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4352 | 2022 |
| 2022-11-22 | Novo Nordisk AS | $180 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4352 | 2022 |
| 2022-11-21 | Janssen Research & Development, LLC | $67,164 | Research payment | Cash or cash equivalent | 2022 | ||
| 2022-11-18 | TerSera Therapeutics LLC | $1,300 | Research payment | Cash or cash equivalent | Xermelo Drug, Oncology | A Phase 2, Multicenter, open-label, safety and efficacy study of Xermelo (telotristat ethyl) plus first-line chemotherap | 2022 |
| 2022-11-18 | TerSera Therapeutics LLC | $1,300 | Research payment | Cash or cash equivalent | Xermelo Drug, Oncology | A Phase 2, Multicenter, open-label, safety and efficacy study of Xermelo (telotristat ethyl) plus first-line chemotherap | 2022 |
| 2022-11-18 | Medical Device Business Services, Inc. | $275 | Research payment | Cash or cash equivalent | ACTIS Device, Ortho-Hip | Actis Total Hip System 2 Year Follow up | 2022 |
| 2022-11-16 | Philips North America LLC | $11,505 | Research payment | Cash or cash equivalent | (9532) PD Other Device, Medical Device | LFQ Phase II Study | 2022 |
| 2022-11-16 | PFIZER INC. | $1,012 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT | 2022 |
| 2022-11-15 | PFIZER INC. | $103,770 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VAC | 2022 |
| 2022-11-15 | PFIZER INC. | $15,820 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB | 2022 |
| 2022-11-08 | Janssen Research & Development, LLC | $7,500 | Research payment | Cash or cash equivalent | An Open label Phase 11b Study to Evaluate the Safety and Pharmacokinetics of JNJ73841937 Lazertinib a Third Generation E | 2022 | |
| 2022-11-05 | PFIZER INC. | $3,899 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIA | 2022 | |
| 2022-11-04 | SANOFI US SERVICES INC. | $121 | Charitable Contribution | Cash or cash equivalent | 2022 | ||
| 2022-11-03 | Novo Nordisk AS | $23 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4352 | 2022 |
| 2022-11-03 | Novo Nordisk AS | $8 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4352 | 2022 |
| 2022-11-02 | PFIZER INC. | $62,074 | Research payment | Cash or cash equivalent | BIOTHERAPEUTICS TARGETING SLIT2ROBO2 SIGNALING PATHWAY TO TREAT PATIENTS WITH CHRONIC KIDNEY | 2022 | |
| 2022-11-02 | G1 Therapeutics, Inc. | $13,767 | Research payment | Cash or cash equivalent | COSELA Drug, ONCOLOGY | A Phase 3, Randomized, Double-Blind Study of COSELA or Placebo in Patients Receiving First- or Second-Line Gemcitabine a | 2022 |
| 2022-11-02 | TerSera Therapeutics LLC | $12,637 | Research payment | Cash or cash equivalent | Xermelo Drug, Oncology | A Phase 2, Multicenter, open-label, safety and efficacy study of Xermelo (telotristat ethyl) plus first-line chemotherap | 2022 |
| 2022-11-01 | PFIZER INC. | $1,940 | Research payment | Cash or cash equivalent | PAXLOVID Drug, INFECTIOUS DISEASES | A PHASE 23 INTERVENTIONAL SAFETY PHARMACOKINETICS AND EFFICACY OPENLABEL MULTICENTER SINGLEARM STUDY TO INVESTIGATE ORAL | 2022 |
| 2022-10-31 | Merck Sharp & Dohme LLC | $6,727 | Research payment | Cash or cash equivalent | Characterization of Systemic and Local Immune Responses to Chlamydia Antigens in Women to support Vaccine Antigen Select | 2022 | |
| 2022-10-31 | Janssen Research & Development, LLC | $3,485 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide Bortezo | 2022 |
| 2022-10-26 | VERTEX PHARMACEUTICALS INCORPORATED | $100,000 | Grant | Cash or cash equivalent | 2022 | ||
| 2022-10-26 | PFIZER INC. | $35,414 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT | 2022 |
| 2022-10-26 | Agios Pharmaceuticals, Inc. | $16,125 | Research payment | Cash or cash equivalent | PYRUKYND Drug, Genetically Defined Disease | A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mita | 2022 |
| 2022-10-26 | Indivior Inc. | $5,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | SUBLOCADE Drug, OUD | 2022 | |
| 2022-10-26 | Agios Pharmaceuticals, Inc. | $3,762 | Research payment | Cash or cash equivalent | PYRUKYND Drug, Genetically Defined Disease | A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mita | 2022 |
| 2022-10-26 | Agios Pharmaceuticals, Inc. | $3,250 | Research payment | Cash or cash equivalent | PYRUKYND Drug, Genetically Defined Disease | A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mita | 2022 |
| 2022-10-25 | PFIZER INC. | $3,190 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIA | 2022 | |
| 2022-10-24 | Janssen Research & Development, LLC | $11,459 | Research payment | Cash or cash equivalent | An Open label Phase 11b Study to Evaluate the Safety and Pharmacokinetics of JNJ73841937 Lazertinib a Third Generation E | 2022 | |
| 2022-10-21 | Novo Nordisk AS | $1,810 | Research payment | Cash or cash equivalent | Ozempic Drug, Diabetes | NN9535-4352 | 2022 |
| 2022-10-21 | Organon Llc | $1,616 | Research payment | Cash or cash equivalent | NEXPLANON Drug, ETONOGESTREL | A Study to Assess Contraceptive Efficacy and Safety of Etonogestrel (ENG) Implant Beyond 3 Years of Use (MK-8415-060) | 2022 |
| 2022-10-14 | PFIZER INC. | $12,814 | Research payment | Cash or cash equivalent | PAXLOVID Drug, INFECTIOUS DISEASES | A PHASE 23 INTERVENTIONAL SAFETY PHARMACOKINETICS AND EFFICACY OPENLABEL MULTICENTER SINGLEARM STUDY TO INVESTIGATE ORAL | 2022 |
| 2022-10-12 | PFIZER INC. | $1,350 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY IN | 2022 |
| 2022-10-06 | PFIZER INC. | $16,091 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT | 2022 |
| 2022-10-06 | ABBVIE INC. | $9,509 | Research payment | Cash or cash equivalent | VENCLEXTA Drug, ONCOLOGY | A Study of Venetoclax and Dexamethasone Compared With Pomalidomide and Dexamethasone in Participants With Relapsed or Re | 2022 |
| 2022-10-06 | PFIZER INC. | $3,880 | Research payment | Cash or cash equivalent | PAXLOVID Drug, INFECTIOUS DISEASES | A PHASE 23 INTERVENTIONAL SAFETY PHARMACOKINETICS AND EFFICACY OPENLABEL MULTICENTER SINGLEARM STUDY TO INVESTIGATE ORAL | 2022 |
| 2022-10-05 | G1 Therapeutics, Inc. | $24,070 | Research payment | Cash or cash equivalent | COSELA Drug, ONCOLOGY | A Phase 3, Randomized, Double-Blind Study of COSELA or Placebo in Patients Receiving First- or Second-Line Gemcitabine a | 2022 |
| 2022-10-03 | NeurAxis, Inc. | $289 | Food and Beverage | Cash or cash equivalent | 2022 | ||
| 2022-10-01 | PFIZER INC. | $29,847 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB | 2022 |
| 2022-10-01 | PFIZER INC. | $18,247 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT | 2022 |
| 2022-09-28 | Abbott Laboratories | $17,987 | Research payment | Cash or cash equivalent | FREESTYLE LIBRE 14 DAY Device, Diabetes Care | EVALUATION OF FLASH CONTINUOUS GLUCOSE MONITORING TO REDUCE HYPERGLYCEMIA IN PEOPLE WITH T2 DIABETES | 2022 |
| 2022-09-28 | Novo Nordisk AS | $1,810 | Research payment | Cash or cash equivalent | Ozempic Drug, Diabetes | NN9535-4352 | 2022 |
| 2022-09-28 | Organon Llc | $1,460 | Research payment | Cash or cash equivalent | NEXPLANON Drug, ETONOGESTREL | A Study to Assess Contraceptive Efficacy and Safety of Etonogestrel (ENG) Implant Beyond 3 Years of Use (MK-8415-060) | 2022 |
| 2022-09-28 | C. R. Bard, Inc. & Subsidiaries | $71 | Debt forgiveness | In-kind items and services | 2022 | ||
| 2022-09-27 | PFIZER INC. | $5,324 | Research payment | Cash or cash equivalent | PAXLOVID Drug, INFECTIOUS DISEASES | A PHASE 23 INTERVENTIONAL SAFETY PHARMACOKINETICS AND EFFICACY OPENLABEL MULTICENTER SINGLEARM STUDY TO INVESTIGATE ORAL | 2022 |
| 2022-09-27 | Novo Nordisk AS | $23 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4352 | 2022 |
| 2022-09-27 | Novo Nordisk AS | $8 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4352 | 2022 |
| 2022-09-26 | Regeneron Pharmaceuticals, Inc. | $2,600 | Research payment | Cash or cash equivalent | A MASTER PROTOCOL ASSESSING THE SAFETY, TOLERABILITY, AND EFFICACY OF ANTI-SPIKE (S) SARS-COV-2 MONOCLONAL ANTIBODIES FO | 2022 | |
| 2022-09-22 | PFIZER INC. | $140,508 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2022 |
| 2022-09-22 | PFIZER INC. | $7,888 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIA | 2022 | |
| 2022-09-21 | PFIZER INC. | $6,756 | Research payment | Cash or cash equivalent | PAXLOVID Drug, INFECTIOUS DISEASES | A PHASE 23 INTERVENTIONAL SAFETY PHARMACOKINETICS AND EFFICACY OPENLABEL MULTICENTER SINGLEARM STUDY TO INVESTIGATE ORAL | 2022 |
| 2022-09-15 | Intercept Pharmaceuticals, Inc. | $158 | Research payment | Cash or cash equivalent | OCALIVA Drug, Hepatology / Gastroenterology | Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) | 2022 |
| 2022-09-15 | Intercept Pharmaceuticals, Inc. | $158 | Research payment | Cash or cash equivalent | OCALIVA Drug, Hepatology / Gastroenterology | Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) | 2022 |
| 2022-09-14 | Indivior Inc. | $5,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | SUBLOCADE Drug, OUD | 2022 | |
| 2022-09-14 | Laminate Medical Technologies inc. | $2,405 | Research payment | Cash or cash equivalent | VasQ External Support Device, B | A Multi-center Prospective Study to Evaluate the Safety and Effectiveness of the VasQ External Support for Arteriovenous | 2022 |
| 2022-09-13 | Laminate Medical Technologies inc. | $11,376 | Research payment | Cash or cash equivalent | VasQ External Support Device, B | A Multi-center Prospective Study to Evaluate the Safety and Effectiveness of the VasQ External Support for Arteriovenous | 2022 |
| 2022-09-12 | Laminate Medical Technologies inc. | $2,600 | Research payment | Cash or cash equivalent | VasQ External Support Device, B | A Multi-center Prospective Study to Evaluate the Safety and Effectiveness of the VasQ External Support for Arteriovenous | 2022 |
| 2022-09-10 | PFIZER INC. | $5,062 | Research payment | Cash or cash equivalent | PAXLOVID Drug, INFECTIOUS DISEASES | A PHASE 23 INTERVENTIONAL SAFETY PHARMACOKINETICS AND EFFICACY OPENLABEL MULTICENTER SINGLEARM STUDY TO INVESTIGATE ORAL | 2022 |
| 2022-09-09 | Janssen Research & Development, LLC | $10,539 | Research payment | Cash or cash equivalent | An Open label Phase 11b Study to Evaluate the Safety and Pharmacokinetics of JNJ73841937 Lazertinib a Third Generation E | 2022 | |
| 2022-09-09 | Takeda Pharmaceuticals U.S.A., Inc. | $4,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2022 | ||
| 2022-09-06 | Janssen Research & Development, LLC | $545 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide Bortezo | 2022 |
| 2022-09-02 | G1 Therapeutics, Inc. | $37,111 | Research payment | Cash or cash equivalent | COSELA Drug, ONCOLOGY | A Phase 3, Randomized, Double-Blind Study of COSELA or Placebo in Patients Receiving First- or Second-Line Gemcitabine a | 2022 |
| 2022-09-02 | PFIZER INC. | $17,974 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALBOCICLIB AFTER CDK AND ENDOCRINE THERAPY PACEA RANDOMIZED PHASE II STUDY OF FULVESTRANT PALBOCICLIB AND AVELUMAB FOR | 2022 |
| 2022-09-02 | PFIZER INC. | $3,975 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIA | 2022 | |
| 2022-09-02 | Novo Nordisk AS | $23 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4352 | 2022 |
| 2022-09-02 | Novo Nordisk AS | $2 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4352 | 2022 |
| 2022-08-25 | Philips North America LLC | $1,911 | Research payment | Cash or cash equivalent | (9532) PD Other Device, Medical Device | ECS Study | 2022 |
| 2022-08-23 | PFIZER INC. | $1,452 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT | 2022 |
| 2022-08-23 | PFIZER INC. | $932 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY IN | 2022 |
| 2022-08-22 | Novo Nordisk AS | $2,692 | Research payment | Cash or cash equivalent | Ozempic Drug, Diabetes | NN9535-4352 | 2022 |
| 2022-08-17 | PFIZER INC. | $13,259 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2022 |
| 2022-08-17 | PFIZER INC. | $13,180 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB | 2022 |
| 2022-08-17 | PFIZER INC. | $1,001 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT | 2022 |
| 2022-08-16 | Medical Device Business Services, Inc. | $50 | Research payment | Cash or cash equivalent | ACTIS Device, Ortho-Hip | Actis Total Hip System 2 Year Follow up | 2022 |
| 2022-08-11 | PFIZER INC. | $6,027 | Research payment | Cash or cash equivalent | PAXLOVID Drug, INFECTIOUS DISEASES | A PHASE 23 INTERVENTIONAL SAFETY PHARMACOKINETICS AND EFFICACY OPENLABEL MULTICENTER SINGLEARM STUDY TO INVESTIGATE ORAL | 2022 |
| 2022-08-10 | PFIZER INC. | $2,313 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB | 2022 |
| 2022-08-05 | PFIZER INC. | $3,258 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIA | 2022 | |
| 2022-08-04 | PFIZER INC. | $16,155 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT | 2022 |
| 2022-08-04 | PFIZER INC. | $16,017 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB | 2022 |
| 2022-08-04 | ABBVIE INC. | $2,853 | Research payment | Cash or cash equivalent | VENCLEXTA Drug, ONCOLOGY | A Study of Venetoclax and Dexamethasone Compared With Pomalidomide and Dexamethasone in Participants With Relapsed or Re | 2022 |
| 2022-08-04 | Intercept Pharmaceuticals, Inc. | $1,709 | Research payment | Cash or cash equivalent | OCALIVA Drug, Hepatology / Gastroenterology | Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) | 2022 |
| 2022-08-03 | G1 Therapeutics, Inc. | $22,074 | Research payment | Cash or cash equivalent | COSELA Drug, ONCOLOGY | A Phase 3, Randomized, Double-Blind Study of COSELA or Placebo in Patients Receiving First- or Second-Line Gemcitabine a | 2022 |
| 2022-08-03 | Indivior Inc. | $5,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | SUBLOCADE Drug, OUD | 2022 | |
| 2022-08-03 | Indivior Inc. | $5,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | SUBLOCADE Drug, OUD | 2022 |
The latest 200 records of 501.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Boston, MA, county Suffolk County, MA, state Massachusetts; placed by its city name.
| Measure | Place (city or town) Boston, MA | County Suffolk County, MA | State Massachusetts |
|---|---|---|---|
| Population B01003 | 666,442 | 785,121 | 7,044,056 |
| Population, 2020 census P1 | 675,647 | 797,936 | 7,029,917 |
| Median age B01002 | 33.3 | 33.9 | 40.0 |
| Under 18 B01001 | 15.1% | 16.0% | 19.4% |
| 65 and over B01001 | 13.0% | 13.3% | 17.9% |
| Households B11001 | 283,374 | 327,167 | 2,785,042 |
| Foreign born B05002 | 27.8% | 29.8% | 18.0% |
| Median household income B19013 | $97,344 | $95,631 | $103,960 |
| Median family income B19113 | $116,436 | $112,072 | $131,675 |
| Per capita income B19301 | $61,698 | $58,636 | $57,897 |
| Poverty rate B17001 | 16.6% | 16.2% | 10.0% |
| Unemployment rate B23025 | 6.1% | 6.3% | 5.2% |
| Civilian labor force B23025 | 402,354 | 468,636 | 3,911,446 |
| Mean commute (minutes) B08013 | 30.3 | 30.9 | 29.1 |
| Bachelor's degree or higher B15003 | 54.9% | 50.6% | 47.3% |
| Housing units B25001 | 310,625 | 357,290 | 3,030,406 |
| Owner-occupied B25003 | 35.7% | 36.5% | 62.5% |
| Renters B25003 | 64.3% | 63.5% | 37.5% |
| Median home value B25077 | $731,700 | $705,800 | $562,100 |
| Median gross rent B25064 | $2,147 | $2,129 | $1,762 |
| White, not Hispanic B03002 | 44.1% | 43.6% | 66.6% |
| Black B03002 | 19.3% | 17.1% | 6.4% |
| Hispanic or Latino B03002 | 19.3% | 23.2% | 13.3% |
| Asian B03002 | 10.3% | 9.2% | 7.3% |
| American Indian and Alaska Native B03002 | 0.1% | 0.1% | 0.1% |
Economy now FRED unemployment 4.3% in Sep 2026 (4.6% a year earlier); per capita personal income $98,700 in 2025, up 27% in five years (+2.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Boston, MA.
Comments